| Serial Number | 79422824 |
| Word Mark | ROUKEN |
| Filing Date | Tuesday, November 26, 2024 |
| Status | 680 - APPROVED FOR PUBLICATION |
| Status Date | Thursday, December 18, 2025 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | NOT AVAILABLE |
| Goods and Services | Scientific and medical research and development services for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, otologic, respiratory, neurological, gastrointestinal, pancreatic, nephrologic, musculoskeletal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; medical research laboratory services; research and development services in the field of antibodies and antibody technology; advisory services relating to the development of chemical reagents; scientific and industrial research services in the fields of biotechnology, pharmaceuticals, immunology, cell engineering, immunoassays and pharmacogenetics; laboratory services namely, research, analysis, characterising and development of therapeutic proteins and human antibodies; development and design of scientific analytical testing methodologies; medical and scientific research into new drug candidates; industrial analysis and research services, in particular for selecting, characterising and preparing immunoglobulins, antibodies or parts thereof; research and development services in the field of immunology; DNA sequencing services being identification of immunogenic sequences and peptides; sequence discovery services in the nature of DNA sequencing technology research; medical and scientific immunotoxicology research and analysis services; medical immunogenicity research and analysis services; pharmaceutical drug development services; development of gene-based medicines; research and development of vaccines and medicines; biological cloning services; biological research and analysis; biological drug development services; laboratory research services relating to pharmaceuticals; providing laboratory research services in the field of biopharmaceuticals; chemical, biochemical, biological and bacteriological research and analysis; medical and scientific research and development services in the field of molecular science; medical and scientific analysis services in the field of molecular biology and molecular genetics; diagnostic services in the field of immunology; providing reagent sample testing and diagnostic services for others for scientific research purposes; scientific consulting services in the fields of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics; providing information about medical research in the fields of biopharmaceuticals, immunology, cell engineering and immunoassays; consulting services for others in the field of design, planning, and implementation project management of scientific research and clinical trials; custom design and development of chemical reagents and biochemical assays; scientific research in the field of genetics and genetic engineering; genetic sequencing analysis services for scientific and medical research purposes; medical and scientific research services analysing the safety and efficacy of new pharmaceuticals; research in the field of cell engineering technology; cell engineering services, namely cell suppression and cell activation; medical and scientific research, development, engineering and testing services in the fields of bioanalytical assays, assay development and antigen binding; medical and scientific research, development, engineering and testing services in the fields of immunotherapies, antibody-based molecules and targeted protein degraders; medical and scientific research, development, engineering and testing services in the fields of molecular biology, biophysics, DNA replication and replication of immune cell interaction in the tumour microenvironment; medical and scientific research, development, engineering and testing services in the field of biopharmaceutical modulating therapeutics; compiling and analysing data for research purposes in the field of medical science and medical consultancy; authentication of data in the field of immunology; cell culture services for scientific and research purposes, for others; DNA sequencing technology research; medical and scientific research, development, engineering and testing services in the fields of immunopharmaceuticals, vaccines and oncology; consultancy, information and advisory services relating to all of the aforesaid services |
| Goods and Services | Chemicals used in industry and science; chemicals and reagents for scientific or medical research purposes; chemical preparations, substances and reagents for analysis in laboratories, not for medical or veterinary purposes; diagnostic preparations, not for medical or veterinary purposes; reagents used for research purposes, in particular, for medical research; reagents used for chemical analyses, not for medical or veterinary purposes; scientific reagents, not for medical or veterinary purposes; chemicals for scientific and research use in the field of immunology; reagents used for scientific and research purposes in the field of immunoserology; diagnostic and testing reagents for scientific use, not for medical or veterinary purposes; immunoassay reagents, other than for medical use; laboratory chemicals and reagents for scientific use and medical research; biochemical reagents used for non-medical purposes; biochemicals being monoclonal antibodies used for non-medical purposes; immunogens, immunoglobulins, antibodies, peptides and proteins for scientific and medical research services; biological activators, namely, preparations for clinical or medical laboratory use; biological preparations for use as assay samples for research analysis purposes in the field of medical research; reagents for use in scientific apparatus for chemical or biological analysis; biochemical reagents commonly known as probes, for detecting and analyzing molecules in protein or nucleotide arrays used for non-medical purposes; diagnostic preparations for scientific or research use; diagnostic reagents for in vitro use in biochemistry, clinical chemistry and microbiology; diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents to monitor toxicity of drugs used for non-medical purposes; laboratory chemicals, namely, an antibody reagent used for the detection of antigens in cell and tissue analysis for in vitro diagnostic use for non-medical purposes; reagents for scientific and research use; assays and reagents for use in genetic research; cell culture reagents for scientific and research use; protein for industrial use; protein in raw material form for scientific and medical research; assays for research purposes; biochemicals, namely, polypeptides for in vitro research use; biochemicals, namely, DNA, RNA and oligonucleotides for in vitro research use; cells for scientific and research use; immune cells for scientific and research use; T cells for scientific and research use; primary cells for scientific and research use; immortalised cells for scientific and research use; biological tissue, namely, blood, stem cells, disease state tissue, healthy donor tissue, healthy donor blood, human biopsy tissue, umbilical cords and placentas for scientific and medical research use |
| Goods and Services | Pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; biological preparations for medical purposes, namely, biological preparations for the diagnoses and treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; large molecules for medical purposes being chemical reagents for medical purposes; biological tissue cultures for medical purposes; biological tissue cultures for medical use; diagnostic preparations for medical purposes, namely, biological tissue; biological preparations for the treatment of cancer; biological preparations for use in cell cultures for medical purposes; mixed biological preparations for the prevention and treatment of infectious diseases; biological and chemical preparations and reagents for medical or veterinary use; antiserums for diagnostic purposes for diagnoses of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; diagnostic reagents for medical use; diagnostic preparations for medical purposes; diagnostic biomarker reagents for medical purposes; in vitro diagnostic preparations for medical use; diagnostic preparations for medical or veterinary purposes; diagnostic reagents and contrast media for medical use; diagnostic agents, preparations and substances for medical purposes; medical diagnostic reagents and assays for testing body fluids for microorganisms; diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; antibodies for medical purposes; in-vivo diagnostic agent used for detection and monitoring of angiogenesis and anti-angiogenic therapy; diagnostic preparations for medical purposes for detecting the presence of malignant, inflammatory and autoimmune disorders and conditions and tissue trauma in humans; reagents for medical use; chemical reagents for medical purposes; reagents for use in medical genetic testing; enzymes for medical purposes; cells for medical or clinical use; culture media for cultivating human cells and microorganism cells for medical purposes; immunoassay reagents for medical use; assay platforms for medical use for detecting and analysing proteins, nucleic acids, small molecules, cells, pathogens and lipids; immunology assays for medical use for detecting and analysing proteins, nucleic acids, small molecules, cells, pathogens and lipids; antigens for medical use; antiviral T cells for medical use; human immune cells, in particular T cells, for medical or clinical purposes; human primary cells for medical and clinical use; immortalised human cells for medical and clinical use; target antigens for medical use; medicinal preparations for the treatment of infectious diseases and for use in oncology; pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system, and for the treatment of inflammatory disorders for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; vaccine preparations; therapeutic vaccines |
| International Class | 001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry. |
| US Class Codes | 001, 005, 006, 010, 026, 046 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, May 1, 2025 |
| Primary Code | 001 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, May 1, 2025 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, May 1, 2025 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Antibody Analytics Limited |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 99 - Other |
| Address | GB |
| Event Date | Event Description |
| Thursday, May 1, 2025 | SN ASSIGNED FOR SECT 66A APPL FROM IB |
| Friday, May 2, 2025 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Friday, May 2, 2025 | APPLICATION FILING RECEIPT MAILED |
| Monday, May 19, 2025 | ASSIGNED TO EXAMINER |
| Thursday, May 22, 2025 | NON-FINAL ACTION WRITTEN |
| Friday, May 23, 2025 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Tuesday, July 15, 2025 | REFUSAL PROCESSED BY MPU |
| Wednesday, July 16, 2025 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Saturday, August 2, 2025 | REFUSAL PROCESSED BY IB |
| Tuesday, August 5, 2025 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Tuesday, August 5, 2025 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Tuesday, August 5, 2025 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Tuesday, August 5, 2025 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Tuesday, August 5, 2025 | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS |
| Saturday, November 29, 2025 | NEW REPRESENTATIVE AT IB RECEIVED |
| Friday, December 12, 2025 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Friday, December 12, 2025 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Friday, December 12, 2025 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Tuesday, December 16, 2025 | FINAL REFUSAL WRITTEN |
| Tuesday, December 16, 2025 | FINAL REFUSAL E-MAILED |
| Tuesday, December 16, 2025 | NOTIFICATION OF FINAL REFUSAL EMAILED |
| Wednesday, December 17, 2025 | TEAS REQUEST FOR RECONSIDERATION RECEIVED |
| Wednesday, December 17, 2025 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, December 17, 2025 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Thursday, December 18, 2025 | APPROVED FOR PUB - PRINCIPAL REGISTER |